MF

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, LYRA, Common, Bronchitis, Disease, MF, New Drug Application, COVID-19, Patient, Smell, Network congestion, CRS, United, Nasal cavity, Pharmacotherapy, Investment, Clinical trial, Therapy, Safety, Sinusitis, ESS, FDA, Food, Pharmaceutical industry

WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.  

Key Points: 
  • WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
  • LYR-220, a larger insert, is designed for CRS patients whose nasal cavity is enlarged due to previous ESS.
  • Cash, cash equivalents and short-term investments were $102.8 million as of December 31, 2023, compared to $102.6 million as of September 30, 2023.
  • The Company recorded an impairment charge of $1.6 million related to long-lived assets for the year ended December 31, 2023.

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 21, 2024
Well, Research, Administration, Development, ASH, EPP, MF, Patient, NTD, Trial of the century, Ruxolitinib, IRON, Anemia, Porphyria, JAK

“The past year has been truly remarkable for Disc and marks another important chapter in our company’s story.

Key Points: 
  • “The past year has been truly remarkable for Disc and marks another important chapter in our company’s story.
  • During 2023, we provided the first evidence of the therapeutic potential of our programs, with positive read-outs in patients for both bitopertin and DISC-0974.
  • The increase was primarily due to the completion of a registered direct offering in February 2023 and a publicly marketed follow-on offering in June 2023.
  • The increase was primarily due to higher operating costs in the current period to support the continued advancement of our pipeline.

Nokia launches new 25G PON fiber modem to accelerate multi-gigabit broadband deployments

Retrieved on: 
Tuesday, March 12, 2024
Element, XGS, GPON, MSA, MF, DF, Internet, AI, PON, Home network, Cable television

New 25G PON fiber modem from Nokia helps operators unlock additional revenue streams through new premium residential, business, and mobile services.

Key Points: 
  • New 25G PON fiber modem from Nokia helps operators unlock additional revenue streams through new premium residential, business, and mobile services.
  • 25G PON allows operators to connect fiber to everything using the same fiber infrastructure to deliver enhanced services and grow revenue.
  • Berlin, Germany – Nokia today announced the launch of a new, symmetrical 25G PON fiber modem.
  • Nokia’s new 25G PON fiber modem allows operators to establish a future-ready network that can immediately address the growing demand for more capacity and enhanced broadband services.

THE ALL-IN-ONE LENS THAT GOES THE DISTANCE: NIKON RELEASES THE NIKKOR Z 28-400MM F/4-8 VR FULL-FRAME SUPER ZOOM

Retrieved on: 
Wednesday, March 27, 2024
Nikon, Sport, VR, MF, Travel, Food, STM, Collection, Nikon Z-mount, Animal, Flower, Telescopic sight

MELVILLE, N.Y., March 27, 2024 /PRNewswire/ -- Today Nikon Inc. announced the release of the NIKKOR Z 28-400mm f/4-8 VR, a supremely versatile high-power super-zoom lens for Nikon Z series full-frame/FX-format mirrorless cameras. This latest addition to the expanding line of NIKKOR Z lenses offers the highest zoom ratio in its class1, making it a must-have for travel, sports, backyard wildlife and more.

Key Points: 
  • MELVILLE, N.Y., March 27, 2024 /PRNewswire/ -- Today Nikon Inc. announced the release of the NIKKOR Z 28-400mm f/4-8 VR, a supremely versatile high-power super-zoom lens for Nikon Z series full-frame/FX-format mirrorless cameras.
  • The NIKKOR Z 28-400mm f/4-8 VR is a high-magnification zoom lens that covers a broad range of focal lengths — from 28mm to 400mm.
  • The new NIKKOR Z 28-400mm f/4-8 VR lens will be available in mid-April for a suggested retail price of $1299.95*.
  • For more information about the latest Nikon products, including the vast collection of NIKKOR Z lenses and the entire line of Z series cameras, please visit Nikonusa.com .

Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI

Retrieved on: 
Thursday, February 29, 2024
Technology, Medical Devices, Software, Audio, Video, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Artificial Intelligence, Pancreatic serous cystadenoma, PV, Multimedia, AI, MF, Friends, Empathy, Education International, Bone marrow, Fatigue, Patient, Family, Headache, Ruxolitinib, MPN, Brain, Medical imaging

Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a group of rare, chronic and progressive blood cancers.

Key Points: 
  • Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a group of rare, chronic and progressive blood cancers.
  • View the full release here: https://www.businesswire.com/news/home/20240229692531/en/
    The Unseen Journey highlights the stories of people living with MPNs who were asked to describe their symptoms and how they impact their lives in their own words.
  • As each patient described their symptoms and experiences, generative AI tools transformed their words into images that visually depict the patient’s most burdensome symptoms.
  • It is important for MPN patients to track their symptoms on a regular basis to help inform conversations with their health care provider.

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Wednesday, February 28, 2024
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Well, Neoplasm, Psoriasis, DecisionDx-UM, Investment, News, Growth, Table, Uveal melanoma, Epidemiology, SCC, Webcast, Diagnosis, Mortality, Woman, Melanoma, Cohort (statistics), Recurrence, BWH, Overalls, Radiation, Metastasis, Mycosis fungoides, GAAP, Journal, Net, Depreciation, PSO, Major depressive disorder, Randomized controlled trial, Atopic dermatitis, Adjustment, Practitioner, ART, Castle, National Comprehensive Cancer Network, Survival, MDD, Workflow, Acquisition, MF, Risk, Medicare, NCCN, Patient, Pharmaceutical industry

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023.
  • DecisionDx-SCC test reports delivered in the quarter were 3,530, compared to 1,845 in the fourth quarter of 2022, an increase of 91%.
  • DecisionDx-UM test reports delivered in the quarter were 405, compared to 432 in the fourth quarter of 2022, a decrease of 6%.
  • Castle Biosciences will hold a conference call on Wednesday, Feb. 28, 2024, at 4:30 p.m. Eastern time to discuss its fourth quarter and full-year 2023 results and provide a corporate update.

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, General Health, Pharmaceutical, Health, Janus, Hercules, BAT, European Commission, EMA, Marketing, Research, New Drug Application, Anemia, Transfusion-dependent anemia, Syndrome, MAA, MF, FDA, Geron Corporation, Imetelstat, Exercise, PDUFA, Loan, Risk, Primary myelofibrosis, Society, MDS, Civil service commission, JAK, History, European Medicines Agency, Webcast, Register, SVB, Patient, Federal, Clinical trial, Corporation, NDA, Depreciation

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.
  • The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 to the NDA.
  • In September 2023, the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for imetelstat in the same proposed indication as the NDA.
  • Geron will host a conference call at 8:00 am ET on Wednesday, February 28, 2024, to discuss business updates and fourth quarter and full year 2023 financial results.

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
WBC, WRN, Lung cancer, RNA, Malignancy, Microsatellite instability, Proteome, Intellectual property, MMR, MPN, Glioblastoma, Neoplasm, Splenomegaly, DMPK, Phosphorylation, HDAC, STAT5, RNA-Seq, WES, Standard of care, Therapy, RecQ helicase, Phenotype, Ruxolitinib, DNA, DNA repair, Pancreatic serous cystadenoma, CDKN2A, Cancer, CRC, PIM, Arginine, MTA, Abstract, PDC, MTAP, Colorectal cancer, CRISPR, PV, MF, MSI-H, Cell, JAK, DNA mismatch repair, Medicine, Patient, Gene, PRMT5, Haematopoiesis, Mesothelioma, Pharmaceutical industry

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Retrieved on: 
Wednesday, February 14, 2024
PD, Development plan, AML, Syndrome, MF, Part, Committee, Safety, NPM1, Therapy, EOD, Pharmacokinetics, Venetoclax, Phases of clinical research, Patient, Clinical trial, Ruxolitinib, Ethics, Pharmaceutical industry

Ultimately, the study will expand to other EU and non-EU countries, covering up to 80 clinical sites globally.

Key Points: 
  • Ultimately, the study will expand to other EU and non-EU countries, covering up to 80 clinical sites globally.
  • RIVER-52 is a multicenter, open-label clinical trial designed to evaluate RVU120 in adult patients with r/r AML and HR-MDS, without alternative therapies.
  • RIVER-52 represents the second of the four planned RVU120 Phase II clinical studies scheduled for launch in H1 2024.
  • In addition to RIVER-52, Ryvu has already started patient treatment in the RIVER-81 study (evaluating RVU120 in combination with venetoclax for treating r/r AML patients).

Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML

Retrieved on: 
Wednesday, January 31, 2024
Pharmacokinetics, Venetoclax, Ruxolitinib, MF, Ethics, Phases of clinical research, Clinical trial, Syndrome, Patient, Safety, ABM, AML, Therapy, Phase, Committee, Optimism, PD, Pharmaceutical industry

The primary goal of the RIVER-81 study will be to evaluate safety and efficacy of RVU120 in combination with venetoclax in r/r AML patients who have failed prior venetoclax treatment.

Key Points: 
  • The primary goal of the RIVER-81 study will be to evaluate safety and efficacy of RVU120 in combination with venetoclax in r/r AML patients who have failed prior venetoclax treatment.
  • The study is part of the RVU120 Development Plan presented in October 2023 and aligns with the company's cash runway to Q1 2026.
  • In H1 2024, Ryvu plans to launch four Phase II RVU120 clinical studies and enroll over 100 patients across the studies by the end of the year.
  • Following RIVER-81, Ryvu intends to initiate the RIVER-52 study (evaluating RVU120 as a monotherapy in patients with genetically defined subtypes of AML and in patients with HR-MDS).